GlaxoSmithKline News and Research

RSS

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Mylan Inc. today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.

27 Mar 2014

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence.

27 Mar 2014

First Edition: March 27, 2014

Today's headlines include more coverage of the emerging details of the Obama administration's decision to allow some consumers to enroll in health coverage after the March 31 deadline.

27 Mar 2014

Communispace launches new business unit for health care companies

Communispace – the leading consumer collaboration agency – today announced the launch of Communispace Health, a new business unit dedicated to helping health care companies collaborate with consumers to create greater impact and develop competitive advantage in the marketplace. Communispace Vice President, Corey Schwartz, has been named Managing Director of Communispace Health.

25 Mar 2014

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

The body clock's natural rhythm could be utilized to improve current therapies to delay the onset of chronic lung diseases.

From The University of Manchester 18 Mar 2014

New drug is effective against superbug MRSA

"I routinely call hospitals and request their yearly antibiotic susceptibility testing data," said Washington University in St. Louis' Timothy Wencewicz. "The log might say, for example, that they've treated hundreds of patients for Acinetobacter baumanni, a bacterium brought into U.S. hospitals by soldiers wounded in the Iraq war, with 30 different antibiotics.

6 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

More than 30 European universities and companies, led by GlaxoSmithKline, are joining forces in a six-year programme funded by the Innovative Medicines Initiative (IMI) for the sum of EUR 85 millions with the aim of developing new antibiotics against Gram-negative pathogens.

14 Feb 2014

Drive for novel antibiotics against gram-negative bacteria

Over 30 European universities, research institutes, and companies, led by GlaxoSmithKline and Uppsala University, are joining forces in a 6 year programme supported by the Innovative Medicines Initiative (IMI) to develop novel antibiotics against Gram-negative pathogens.

13 Feb 2014

Scientists receive €85 million international drive to develop new and effective drugs

An increasing biological resistance to antibiotics treatment is to be countered by Aston University scientists who will lead a €85 million international drive to develop new and effective drugs.

12 Feb 2014

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals Incorporated today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

11 Feb 2014

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

3 Feb 2014

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

The first clinical study of a low-cost neonatal breathing system created by Rice University bioengineering students demonstrated that the device increased the survival rate of newborns with severe respiratory illness from 44 percent to 71 percent.

31 Jan 2014

Study shows high-fiber diet reduces risk of colon problems

Scientists have more reasons for you to eat fiber and not abuse antibiotics.

17 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.

7 Jan 2014

GSK team wins Drug Discovery of Year award for developing trametinib for malignant melanoma

The British Pharmacological Society proudly announces that its Drug Discovery of the Year award has been won by the team at GlaxoSmithKline (GSK) responsible for the development of trametinib - a new treatment for malignant melanoma (a type of skin cancer).

19 Dec 2013

Collaborative pharmaceutical project focusing on paediatric formulation development gets go-ahead

A collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant.

19 Dec 2013

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company's investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline's orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

18 Dec 2013

Glaxo to stop paying docs worldwide for drug advocacy

The pharmaceutical giant ended the practice in the U.S. in 2011.

18 Dec 2013

GlaxoSmithKline News and Research

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

First Edition: March 27, 2014

Communispace launches new business unit for health care companies

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

New drug is effective against superbug MRSA

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

Drive for novel antibiotics against gram-negative bacteria

Scientists receive €85 million international drive to develop new and effective drugs

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Bubble CPAP device increases survival rate of newborns with severe respiratory illness

Study shows high-fiber diet reduces risk of colon problems

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

GSK team wins Drug Discovery of Year award for developing trametinib for malignant melanoma

Collaborative pharmaceutical project focusing on paediatric formulation development gets go-ahead

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Glaxo to stop paying docs worldwide for drug advocacy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News